The pace is picking up in the fight to develop a Covid-19 vaccine; more companies are beginning to form collaborations and begin clinical trials to ensure rapid development, as well as sufficient production capacity. There is optimism in the number of vaccine candidates and techniques in progress. However, the history of vaccine development highlights roadblocks and setbacks, which are almost guaranteed, indicating that a finished product will not likely be readily available this year.
Despite Gilead releasing positive (yet inconclusive) data from its antiviral remdesivir trial, a vaccine remains the ultimate goal to prevent future outbreaks of the deadly Covid-19. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
